MTOR and neoplasm: Within the combined caveolin-1/pAKT data set (n=160), 23/26 (88%) of the caveolin-1-positive tumours also coexpressed pAKT, while within the combined data sets of caveolin-1/pmTOR (n=96), caveolin-1/pS6 (n=106) and caveolin-1/p4E-BP1 (n=143) the number of caveolin-1-positive tumours that coexpressed the selected individual AKT/mTOR pathway marker was 43, 35 and 52%, respectively (Figure 3).